Reaction Details Report a problem with these data
Target
Sodium/glucose cotransporter 2
Ligand
BDBM50265182
Substrate
n/a
Meas. Tech.
ChEMBL_496716 (CHEMBL1005353)
IC50
15050±n/a nM
Citation
 Lansdell, MI; Burring, DJ; Hepworth, D; Strawbridge, M; Graham, E; Guyot, T; Betson, MS; Hart, JD Design and synthesis of fluorescent SGLT2 inhibitors. Bioorg Med Chem Lett 18:4944-7 (2008) [PubMed]  Article 
Target
Name:
Sodium/glucose cotransporter 2
Synonyms:
Na(+)/glucose cotransporter 2 | SC5A2_HUMAN | SGLT2 | SLC5A2 | Sodium-Dependent Glucose Cotransporter 2 (SGLT2) | Sodium/glucose cotransporter 1 (SGLT1) | Solute carrier family 5 member 2
Type:
Protein
Mol. Mass.:
72902.00
Organism:
Homo sapiens (Human)
Description:
P31639
Residue:
672
Sequence:
MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGRSMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTAGVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIALLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQRCLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVGCSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDRELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRVNEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLLTLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQAPAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLMMAVAVFLWGFYA
  
Inhibitor
Name:
BDBM50265182
Synonyms:
5-(6-((4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)benzyl)(methyl)amino)-6-oxohexylcarbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid | CHEMBL466749
Type:
Small organic molecule
Emp. Form.:
C48H47ClN2O12
Mol. Mass.:
879.346
SMILES:
CN(Cc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1)C(=O)CCCCCNC(=O)c1ccc(c(c1)C(O)=O)-c1c2ccc(O)cc2oc2cc(=O)ccc12 |r,wU:17.18,22.23,15.15,wD:24.26,20.21,(8.74,-15.51,;8.75,-13.97,;7.43,-13.19,;6.08,-13.95,;6.07,-15.47,;4.74,-16.22,;3.43,-15.44,;2.1,-16.2,;.75,-15.43,;-.59,-16.19,;-1.92,-15.43,;-1.92,-13.89,;-.58,-13.11,;.76,-13.89,;2.09,-13.12,;-3.26,-16.19,;-4.59,-15.41,;-5.92,-16.19,;-7.25,-15.43,;-8.59,-16.2,;-5.92,-17.74,;-7.25,-18.51,;-4.59,-18.5,;-4.59,-20.04,;-3.26,-17.74,;-1.92,-18.51,;3.44,-13.92,;4.76,-13.17,;10.1,-13.21,;10.11,-11.67,;11.42,-13.99,;12.77,-13.23,;14.09,-14.01,;15.44,-13.25,;16.76,-14.03,;18.11,-13.27,;19.43,-14.05,;19.42,-15.6,;20.78,-13.31,;22.1,-14.11,;23.45,-13.37,;23.48,-11.83,;22.15,-11.03,;20.81,-11.78,;21.38,-9.7,;19.84,-9.69,;22.16,-8.36,;24.82,-11.09,;26.14,-11.88,;26.11,-13.41,;27.41,-14.2,;28.76,-13.46,;30.08,-14.26,;28.79,-11.94,;27.49,-11.15,;27.53,-9.61,;26.2,-8.81,;26.24,-7.27,;24.92,-6.47,;24.96,-4.93,;23.56,-7.21,;23.53,-8.75,;24.85,-9.55,)|
Structure:
Search PDB for entries with ligand similarity: